BR112013029182A2 - método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas - Google Patents

método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas

Info

Publication number
BR112013029182A2
BR112013029182A2 BR112013029182A BR112013029182A BR112013029182A2 BR 112013029182 A2 BR112013029182 A2 BR 112013029182A2 BR 112013029182 A BR112013029182 A BR 112013029182A BR 112013029182 A BR112013029182 A BR 112013029182A BR 112013029182 A2 BR112013029182 A2 BR 112013029182A2
Authority
BR
Brazil
Prior art keywords
solid malignancies
including advanced
metastatic
treating
malignancies including
Prior art date
Application number
BR112013029182A
Other languages
English (en)
Inventor
Rudolph Dorothea
Michael Munzert Gerd
Taube Tillmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46046245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013029182(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112013029182A2 publication Critical patent/BR112013029182A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

resumo patente de invenção: "método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas". a presente invenção refere-se ao uso de volasertibe ou um sal do mesmo ou o hidrato do mesmo para o tratamento de pacientes que estão sofrendo de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas compreendendo uma administração de frequência elevada de volasertibe de acordo com uma posologia específica.
BR112013029182A 2011-05-13 2012-05-11 método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas BR112013029182A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11165958 2011-05-13
PCT/EP2012/058704 WO2012156283A1 (en) 2011-05-13 2012-05-11 Method for treatment of solid malignancies including advanced or metastatic solid malignancies

Publications (1)

Publication Number Publication Date
BR112013029182A2 true BR112013029182A2 (pt) 2017-01-31

Family

ID=46046245

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029182A BR112013029182A2 (pt) 2011-05-13 2012-05-11 método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas

Country Status (15)

Country Link
US (3) US20130131069A1 (pt)
EP (1) EP2707001B1 (pt)
JP (1) JP2014513144A (pt)
KR (1) KR20140025460A (pt)
CN (1) CN103533941A (pt)
AR (1) AR086390A1 (pt)
AU (1) AU2012257833A1 (pt)
BR (1) BR112013029182A2 (pt)
CA (1) CA2835717A1 (pt)
CL (1) CL2013003198A1 (pt)
EA (1) EA201301265A1 (pt)
IL (1) IL228882A0 (pt)
MX (1) MX2013013059A (pt)
UY (1) UY34065A (pt)
WO (1) WO2012156283A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0797333A (ja) * 1993-08-04 1995-04-11 Takeda Chem Ind Ltd 超分子構造型集合体
PT1599478E (pt) 2003-02-26 2007-05-31 Boehringer Ingelheim Pharma Di-hidropteridinonas, proceso para a sua preparação e a sua utilização como medicamento
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative

Also Published As

Publication number Publication date
CA2835717A1 (en) 2012-11-22
UY34065A (es) 2012-11-30
EP2707001A1 (en) 2014-03-19
US20130131069A1 (en) 2013-05-23
EP2707001B1 (en) 2016-12-21
EA201301265A1 (ru) 2014-05-30
AR086390A1 (es) 2013-12-11
MX2013013059A (es) 2014-02-20
IL228882A0 (en) 2013-12-31
WO2012156283A1 (en) 2012-11-22
AU2012257833A1 (en) 2013-10-31
CN103533941A (zh) 2014-01-22
US20190290652A1 (en) 2019-09-26
KR20140025460A (ko) 2014-03-04
JP2014513144A (ja) 2014-05-29
US20160303131A1 (en) 2016-10-20
CL2013003198A1 (es) 2014-06-20

Similar Documents

Publication Publication Date Title
BR112013029182A2 (pt) método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas
PH12016502355A1 (en) Pharmaceutical composition
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MY190408A (en) Compositions and methods for treating cns disorders
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
BR112015008447A2 (pt) métodos para tratar câncer
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
AU2011328009A8 (en) Compounds and methods for treating pain
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
PH12016502352A1 (en) Pharmaceutical composition
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX2013012588A (es) Inhibidores de cinasa.
PH12016502353A1 (en) Pharmaceutical composition
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
BR112012031634A2 (pt) composto, composição farmacêutica, uso de um composto, e método para tratar um paciente que sofre de ou susceptível a um distúrbio
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
EA201370230A1 (ru) Новые ингибиторы rock
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
BR112015007095A2 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados
MX357770B (es) Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer.
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]